NCT06361186

Proximod Pharmacokinetics In Healthy Subjects

A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Proximod in Healthy Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 134 (actual)
• Sponsor: Longevity Inc. · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects. The main questions it arms to answer are: 1. to evaluate the safety and tolerance of Proximod in healthy subjects after single or repeated doses. 2. to learn the pharmacodynamics of Proximod in healthy subjects after single or repeated doses. 3. to evaluation of the effect of food on the pharmacokinetics of Proximod in healthy subjects Participants will receive test tablets or placebo at the indicated date and collect blood samples.

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	Proximod	Single and multiple-dose to establish the safety and PK profile
DRUG	Placebo	Placebo controlled

Timeline

• Start date: 2017-09-14
• Primary completion: 2017-11-01
• Completion: 2021-06-22
• First posted: 2024-04-11
• Last updated: 2024-04-11

Locations

1 site across 1 country: China